Everyone knows China dominates CDMOs. Fewer people ask why. It wasn't cheap labour. That advantage faded years ago. India doesn't need to recreate that scale overnight. It only needs to become one of the few manufacturing ecosystems global pharma is comfortable depending on.
The Biosecure Act isn’t just another policy update – it could reshape the global CDMO landscape.
For decades, China dominated pharma outsourcing.
Today, geopolitical risk and supply chain diversification are pushing global innovators to look beyond a single manufacturing hub.
And India is already part of that shift way ahead of others.
• Approx. 45% of US generics supplied by India.
• India has the most USFDA-approved plants outside the US.
• A $195.3B bioeconomy, growing at a 17.8% CAGR since 2020 – independent of any US policy.
Swipe through to understand why this isn’t just about the Bio secure Act – it’s one of the biggest structural shifts shaping the future of global pharma.
To READ in detail click here.
